TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6522192

Group type: EXPERIMENTAL
Intervention: Free social interaction (interactive condition)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Waiting expectancy (expected waiting)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Interactive conditions
Number of subjects: 72
Study: 31620886

Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus plantarum L-137 (10 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 100
Study: 29096234

Group type: EXPERIMENTAL
Intervention: Integrated physical activity (task relevant)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nonintegrated physical activity (task nonrelevant)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Observing integrated physical activity
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional sedentary teaching
Number of subjects: 120
Study: 27491669

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Conventional pulmonary rehabilitation using a total body recumbent stepper (TBRS)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Combined Tai Chi and TBRS
Number of subjects: 4

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 4
Study: 24857206

Group type: EXPERIMENTAL
Intervention: TAE regimen (pirarubicin + cytarabine + etoposide)
Number of subjects: 56

Group type: COMPARATOR
Intervention: MAE regimen (mitoxantrone + cytarabine + etoposide)
Number of subjects: 56
Study: 22784345

Group type: EXPERIMENTAL
Intervention: Ginger combination (340 mg EV.EXT 35 Zingiber officinalis extract)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Diclofenac (100 mg daily)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups (ginger and diclofenac)
Number of subjects: 43
Study: 20357732

Group type: COMPARATOR
Intervention: Antimicrobials (cefuroxim, ceftibuten, and others) for 5 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (captopril and enalapril)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined immunosuppressants for crescentic poststreptococcal glomerulonephritis
Number of subjects: 9
Study: 17509728

Group type: EXPERIMENTAL
Intervention: High-protein low-carbohydrate (HPLC) diet
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-protein high-carbohydrate (LPHC) diet
Number of subjects: 25
Study: 15616085

Group type: COMPARATOR
Intervention: General anesthesia (GA) and postoperative opioid analgesia (morphine 0.1 mg/kg bolus and patient‐controlled infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GA and paravertebral anesthesia and analgesia (PVAA) (72‐h infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: GA and postoperative opioid analgesia (morphine 0.1 mg/kg bolus and patient‐controlled infusion)
Number of subjects: 30
Study: 12172345

Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9668734

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 8560160

Group type: EXPERIMENTAL
Intervention: 0.05% levocabastine nasal spray, twice daily for four weeks
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo nasal spray, twice daily for four weeks
Number of subjects: 262
Study: 2231883

Group type: EXPERIMENTAL
Intervention: Carboplatin (400 mg/m² every 28 days)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: CHIP (270 mg/m² every 28 days)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study: 673643

Group type: EXPERIMENTAL
Intervention: Rational-emotive therapy with rational-emotive imagery
Number of subjects: 11

Group type: COMPARATOR
Intervention: Rational-emotive therapy without imagery
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combined groups (both interventions)
Number of subjects: 11
Study: 31989241

Group type: EXPERIMENTAL
Intervention: Info + Spatial +
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Info + Spatial ‐
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Info‐Spatial +
Number of subjects: 30
Study: 31259488

Group type: EXPERIMENTAL
Intervention: Vena cava filter placement within the first 72 hours after admission
Number of subjects: 240

Group type: COMPARATOR
Intervention: No filter placement (control group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Vena cava filter placement in patients who did not receive prophylactic anticoagulation within 7 days
Number of subjects: 240

Group type: COMPARATOR
Intervention: No filter placement in patients who did not receive prophylactic anticoagulation within 7 days (control group)
Number of subjects: 240
Study: 27807903

Group type: EXPERIMENTAL
Intervention: Sodium oxybate 4.5 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium oxybate 6 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium oxybate 9 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26303520

Group type: EXPERIMENTAL
Intervention: Perioperative antibiotic prophylaxis with ciprofloxacin 2 × 500 mg p.o. for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: No perioperative antibiotic prophylaxis
Number of subjects: 40
Study: 23201425

Group type: EXPERIMENTAL
Intervention: Mobilization and Tactile Stimulation (MTS)
Number of subjects: 8
Study: 21208433

Group type: EXPERIMENTAL
Intervention: Multi-component intervention for smoking cessation and CVD risk reduction
Number of subjects: 250

Group type: COMPARATOR
Intervention: Telephone-based minimal intervention focusing on smoking cessation
Number of subjects: 250
Study: 18573923

Group type: EXPERIMENTAL
Intervention: Medication management alone (MedMgt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior therapy alone (Beh)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of medication management and behavior therapy (Comb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community comparison of treatment 'as usual' (CC)
Number of subjects: 0
Study: 16491266

Group type: COMPARATOR
Intervention: 200 mg BH4
Number of subjects: 18

Group type: COMPARATOR
Intervention: 500 mg BH4
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12919178

Group type: EXPERIMENTAL
Intervention: Zolpidem (5 mg oral dose) in elderly men
Number of subjects: 40

Group type: COMPARATOR
Intervention: Zolpidem (5 mg oral dose) in young men
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Zolpidem (5 mg oral dose) in elderly women
Number of subjects: 40

Group type: COMPARATOR
Intervention: Zolpidem (5 mg oral dose) in young women
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Testosterone levels in elderly men
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Testosterone co-incubation with zolpidem in vitro
Number of subjects: 40
Study: 11146071

Group type: EXPERIMENTAL
Intervention: Elective abdominal delivery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Spontaneous vaginal delivery after 20 min of external fetal heart rate monitoring
Number of subjects: 70
Study: 9203230

Group type: EXPERIMENTAL
Intervention: Yohimbine (0.4 mg/kg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: m-Chlorophenylpiperazine (mCPP, 0.1 mg/kg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 35
Study: 8202885

Group type: EXPERIMENTAL
Intervention: Combined nebulised salbutamol (5 mg/dose) and aminophylline infusion (0.6‐0.9 mg/kg/hour)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nebulised salbutamol alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined treatment (salbutamol + aminophylline)
Number of subjects: 25
Study: 3300103

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy with MTX and 5-FU followed by systemic CMFV chemotherapy (therapy arm A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Systemic CMFV chemotherapy only (therapy arm B)
Number of subjects: 43
Study: 2252358

Group type: EXPERIMENTAL
Intervention: Transurethral resection followed by intravesical instillation of Calmette-Guerin bacillus (BCG group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Transurethral resection alone (TUR group)
Number of subjects: 75
Study: 813053

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid
Number of subjects: 12
Study: 31831088

Group type: EXPERIMENTAL
Intervention: High-glycaemic index breakfast
Number of subjects: 13

Group type: COMPARATOR
Intervention: No breakfast consumption
Number of subjects: 13
Study: 30837256

Group type: EXPERIMENTAL
Intervention: Minimally invasive staged segmental artery coil embolisation (MIS2ACE)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard aneurysm repair
Number of subjects: 500
Study: 28832602

Group type: EXPERIMENTAL
Intervention: Individualism-primed task
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Collectivism-primed task
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: No-prime task
Number of subjects: 207
Study: 25909788

Group type: EXPERIMENTAL
Intervention: Cellex (0.1 mg subcutaneously once a day for the first 10 days and from 21 to 27 days)
Number of subjects: 180
Study: 23355629

Group type: EXPERIMENTAL
Intervention: Olmesartan (10-40 mg daily)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Control treatment (not including ARBs or ACE inhibitors)
Number of subjects: 469
Study: 21296638

Group type: EXPERIMENTAL
Intervention: Clenching condition
Number of subjects: 20

Group type: COMPARATOR
Intervention: No tooth-contact condition
Number of subjects: 20
Study: 19679450

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS treatment of the left temporo‐parietal region
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS treatment of the bilateral temporo‐parietal regions
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combined rTMS treatment (bilateral and left)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 17710816

Group type: EXPERIMENTAL
Intervention: Peeling tongue fur
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thick tongue fur
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal tongue fur
Number of subjects: 0
Study: 12657988

Group type: EXPERIMENTAL
Intervention: Early Intervention Program (EIP) with home visitation by public health nurses (PHNs)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Traditional Public Health Nursing Care (TPHNC)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Early Intervention Program (EIP)
Number of subjects: 101
Study: 10773500

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: Dolasetron 25 mg
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: Dolasetron 50 mg
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: Dolasetron 100 mg
Number of subjects: 1946

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1946
Study: 8778552

Group type: EXPERIMENTAL
Intervention: Revised Physical Activity Readiness Questionnaire (rPARQ)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Physical Activity Readiness Questionnaire (PARQ)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Responses for six matched questions
Number of subjects: 193
Study: 1795004

Group type: EXPERIMENTAL
Intervention: Oral ifosfamide (1 g/m2 or 1.5 g/m2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous ifosfamide (1 g/m2 or 1.5 g/m2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral ifosfamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous ifosfamide
Number of subjects: 12
Study: 6321674

Group type: EXPERIMENTAL
Intervention: Synthetic long-acting ACTH (1 mg IM given 24 hours, 12 hours, and immediately preceding cisplatin)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Chlorpromazine (50 mg IM)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31672419

Group type: EXPERIMENTAL
Intervention: Oral transmucosal dexmedetomidine 0.5 µg.kg−1 (Group DEX I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral transmucosal dexmedetomidine 1 µg.kg−1 (Group DEX II)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral transmucosal dexmedetomidine (both DEX I and DEX II)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline placebo (Group C)
Number of subjects: 90
Study: 28901678

Group type: EXPERIMENTAL
Intervention: ImpulsE intervention to improve inhibitory control and emotion regulation abilities
Number of subjects: 69

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT) based treatment as usual
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: ImpulsE intervention
Number of subjects: 69
Study: 25927239

Group type: EXPERIMENTAL
Intervention: Day-clinic psychotherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Inpatient psychotherapy
Number of subjects: 44
Study: 22845337

Group type: EXPERIMENTAL
Intervention: APN follow up telephone calls for week 8 postdischarge
Number of subjects: 139

Group type: COMPARATOR
Intervention: Routine hospital discharge care
Number of subjects: 139
Study: 21605352

Group type: EXPERIMENTAL
Intervention: Early lens extraction with intraocular lens implantation
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard care (laser iridotomy surgery and medical treatment)
Number of subjects: 400
Study: 19397664

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo cream (Aqueous)
Number of subjects: 94
Study: 16940886

Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg + pancreatic enzymes 10,000 IU lipase tid (treatment A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg + pancreatic enzymes 20,000 IU lipase tid (treatment B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 16
Study: 15236618

Group type: EXPERIMENTAL
Intervention: APV/RTV-containing regimen
Number of subjects: 40
Study: 10859579

Group type: EXPERIMENTAL
Intervention: Anticoagulation services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (not explicitly mentioned but implied as control)
Number of subjects: 0
Study: 9379661

Group type: EXPERIMENTAL
Intervention: Normal-tension glaucoma (NTG)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 1491169

Group type: EXPERIMENTAL
Intervention: Walking with a load of 25 kg at 5 km h‐1
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Walking with a load of 20 kg at physical work
Number of subjects: 5
Study: 3995531

Group type: EXPERIMENTAL
Intervention: Clebopride (2 mg)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 30917698

Group type: EXPERIMENTAL
Intervention: BMMSC
Number of subjects: 41

Group type: COMPARATOR
Intervention: BMMNC
Number of subjects: 41

Group type: COMPARATOR
Intervention: NS
Number of subjects: 41
Study: 30926986

Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (GTE) - 4 capsules containing 1315 mg total catechins including 843 mg epigallocatechin‐3‐gallate daily for 1 year
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo - similar capsules containing no tea catechins
Number of subjects: 538
Study: 28427299

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS + Physical Therapy (PT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 0
Study: 24866258

Group type: EXPERIMENTAL
Intervention: Educational intervention on folic acid (FA) supplements at the 6-month visit.
Number of subjects: 413

Group type: COMPARATOR
Intervention: Control group (no intervention) at the 11-month visit.
Number of subjects: 413
Study: 23308186

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or IM IFNβ‐1a
Number of subjects: 0
Study: 21654755

Group type: EXPERIMENTAL
Intervention: Azelnidipine (8 mg/day increased to 16 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg/day increased to 5 mg/day)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 67
Study: 18267998

Group type: EXPERIMENTAL
Intervention: Portion-controlled meal replacement diet (PCD)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both groups (PCD and SD)
Number of subjects: 119
Study: 16949481

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 300
Study: 12890109

Group type: EXPERIMENTAL
Intervention: Metronidazole 0.75% gel
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 10710849

Group type: EXPERIMENTAL
Intervention: Participants' assessed need for cognition
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Social accountability
Number of subjects: 112
Study: 9180240

Group type: EXPERIMENTAL
Intervention: Atorvastatin (2.5, 5, 10, 20, 40, or 80 mg/day)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering diet (NIH National Cholesterol Education Program Step 1 diet or more rigorous diet)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 8299665

Group type: EXPERIMENTAL
Intervention: 800 mg of powdered garlic (coated tablets) daily for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Garlic versus placebo
Number of subjects: 60
Study: 3575019

Group type: EXPERIMENTAL
Intervention: Continuous transcutaneous oxygen tension (tcPO2) monitoring
Number of subjects: 296

Group type: COMPARATOR
Intervention: Standard care (tcPO2 monitored only during acute illness)
Number of subjects: 296
Study: 29325502

Group type: EXPERIMENTAL
Intervention: Rehearsal group (CT scans loaded into an endovascular simulator)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (routine carotid stenting without rehearsal)
Number of subjects: 15
Study: 26929445

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10mg BID
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5mg BID
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Adalimumab 40mg every 2 weeks
Number of subjects: 717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study: 23629597

Group type: EXPERIMENTAL
Intervention: MDIMST
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: LTrP‐I
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo‐sham
Number of subjects: 78
Study: 24358287

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion of ingesting an appetizing meal
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion of ingesting an unappetizing meal
Number of subjects: 62

Group type: COMPARATOR
Intervention: Relaxation while concentrating on an appetizing meal
Number of subjects: 62

Group type: COMPARATOR
Intervention: Relaxation while concentrating on an unappetizing meal
Number of subjects: 62
Study: 19931075

Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: highly purified menotropin (HP-hMG)
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: rFSH plus HP-hMG
Number of subjects: 1028

Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 1028

Group type: COMPARATOR
Intervention: HP-hMG
Number of subjects: 1028
Study: 18621393

Group type: EXPERIMENTAL
Intervention: TIV+PCV7 (influenza plus pneumococcal conjugate vaccination)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: TIV+plac (influenza plus placebo vaccination)
Number of subjects: 579

Group type: COMPARATOR
Intervention: HBV+plac (control hepatitis B virus vaccination plus placebo)
Number of subjects: 579
Study: 16627459

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 176

Group type: COMPARATOR
Intervention: Class IC AADs
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Ramp therapy
Number of subjects: 176

Group type: COMPARATOR
Intervention: Burst+ ATP therapy
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Major clinical events
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Medication toxicity
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Symptoms
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: AF burden
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Quality-of-life
Number of subjects: 176
Study: 14670764

Group type: EXPERIMENTAL
Intervention: Obese children with obstructive sleep related disordered breathing (SDB)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal weight children
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Presence of pharyngeal lymphoid tissue in obese children
Number of subjects: 46
Study: 10962588

Group type: EXPERIMENTAL
Intervention: Bug Busting method (mechanical removal by wet combing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single application insecticide product
Number of subjects: 0
Study: 7633976

Group type: EXPERIMENTAL
Intervention: Fibrin sealant as a topical haemostatic agent
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no fibrin sealant)
Number of subjects: 17
Study: 2677123

Group type: EXPERIMENTAL
Intervention: Various treatments for C. pylori gastritis and NUD
Number of subjects: 14

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 14
Study: 309095

Group type: EXPERIMENTAL
Intervention: Combined prednisone (29 mg/day) and cyclophosphamide (107 mg/day) for six months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prednisone (40 mg/day) for six months
Number of subjects: 50
Study: 30921466

Group type: EXPERIMENTAL
Intervention: Random modulation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: No modulation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 6s-6s modulation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fixed frequency
Number of subjects: 39
Study: 28822253

Group type: EXPERIMENTAL
Intervention: New Orleans Intervention Model (NIM)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Social work 'services as usual'
Number of subjects: 63
Study: 26154338

Group type: EXPERIMENTAL
Intervention: Home Telehealth (HT) system
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 302